Nicholas Hoffman & Company LLC. Sells 1,544 Shares of Johnson & Johnson (NYSE:JNJ)

Nicholas Hoffman & Company LLC. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.6% during the third quarter, Holdings Channel.com reports. The fund owned 32,381 shares of the company’s stock after selling 1,544 shares during the period. Nicholas Hoffman & Company LLC.’s holdings in Johnson & Johnson were worth $5,248,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Capital Wealth Advisors bought a new position in shares of Johnson & Johnson in the 3rd quarter valued at $200,000. Jacobsen Capital Management increased its stake in shares of Johnson & Johnson by 12.1% in the 3rd quarter. Jacobsen Capital Management now owns 3,036 shares of the company’s stock valued at $492,000 after purchasing an additional 328 shares during the last quarter. Fidelis Capital Partners LLC increased its stake in shares of Johnson & Johnson by 8.1% in the 3rd quarter. Fidelis Capital Partners LLC now owns 28,760 shares of the company’s stock valued at $4,770,000 after purchasing an additional 2,155 shares during the last quarter. Valmark Advisers Inc. increased its stake in shares of Johnson & Johnson by 1.4% in the 3rd quarter. Valmark Advisers Inc. now owns 25,040 shares of the company’s stock valued at $4,058,000 after purchasing an additional 338 shares during the last quarter. Finally, Bay Rivers Group increased its stake in shares of Johnson & Johnson by 2.3% in the 3rd quarter. Bay Rivers Group now owns 4,223 shares of the company’s stock valued at $684,000 after purchasing an additional 94 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.3 %

JNJ stock opened at $160.62 on Thursday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The stock’s 50 day moving average is $163.44 and its 200-day moving average is $155.32. The firm has a market capitalization of $386.56 billion, a PE ratio of 10.01, a P/E/G ratio of 2.90 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.46% and a net margin of 19.14%. Johnson & Johnson’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company posted $2.66 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.09%. Johnson & Johnson’s payout ratio is presently 30.92%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Wells Fargo & Company lifted their target price on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Finally, The Goldman Sachs Group cut their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Six equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $175.93.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.